P3.02-027 Lung Adenocarcinoma Patient with EGFR 19 Exon Insert Mutation: I740_K745insIPVAIK and Its Response to Icotinib: A Case Report

MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion

The findings of EGFR mutations and the development of targeted therapies have significantly improved the overall survival of lung cancer patients. Still, the prognosis remains poor, so we need to know more about the genetic alterations in lung cancer. MicroRNAs are dysregulated in lung cancer, and some of them can regulate EGFR. So it is very important to predict the candidate microRNAs that ta...

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein encoded by a gene located in the short arm of chromosome 7. This study aimed to investigate the clinicopathologic characteristics of classic EGFR exon mutation in Chinese patients with TMN stage III lung adenocarcinoma who received radical surgery. A total of 1,801 lung adenocarcinomas were analyzed for mutations in EGFR; 3...

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.

Mutations in the epidermal growth factor receptor (EGFR) gene occur in ∼10%–20% of non-small-cell lung carcinoma (NSCLC) patients, specifically adenocarcinoma, and are associated with response to EGFR tyrosine kinase inhibitors (TKI) such as erlotinib and gefitinib. In contrast to NSCLC, EGFR mutations have rarely been reported in small-cell lung carcinoma (SCLC) [1]. The identification of a pa...

New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.

Icotinib is a new oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We report on a 49-year-old man with recurrent lung adenocarcinoma treated with icotinib. The patient obtained a partial remission in 4 weeks that was maintained 14 months. Retrospective examination of EGFR mutations confirmed he had a sensitive mutation (exon 19 deletion). This case supports that ico...

Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation